MYB rearrangement and clinicopathologic characteristics in head and neck adenoid cystic carcinoma

被引:56
作者
Rettig, Eleni M. [1 ]
Tan, Marietta [1 ]
Ling, Shizhang [1 ]
Yonescu, Raluca [2 ]
Bishop, Justin A. [2 ]
Fakhry, Carole [1 ,3 ,4 ]
Ha, Patrick K. [1 ,3 ]
机构
[1] Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21205 USA
[2] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA
[3] Greater Baltimore Med Ctr, Milton J Dance Jr Head & Neck Ctr, Baltimore, MD USA
[4] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA
关键词
Adenoid cystic carcinoma; salivary gland neoplasms; MYB; MYB-NFIB fusion gene; minor salivary glands; survival; disease-free survival; SALIVARY-GLANDS; NFIB; RECURRENCE; EXPRESSION; PREDICTORS; SURVIVAL; FUSION; RADIATION; SURGERY; THERAPY;
D O I
10.1002/lary.25356
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
ObjectivesSalivary gland adenoid cystic carcinoma (ACC) is rare, aggressive, and challenging to treat. Many ACCs have a t(6;9) chromosomal translocation resulting in a MYB-NFIB fusion gene, but the clinical significance is unclear. The purposes of this study were to describe the clinicopathologic factors impacting survival and to determine the prevalence and clinical significance of MYB-NFIB fusion. Study DesignCase series. MethodsMedical records of patients treated for ACC of the head and neck from 1974 to 2011 were reviewed and clinicopathologic data recorded. Fluorescence in situ hybridization (FISH) was used to detect MYB rearrangement in archival tumor tissue as a marker of MYB-NFIB fusion. ResultsOne hundred fifty-eight patients were included, with median follow-up 75.1 months. Median overall survival was 171.5 months (95% confidence interval [CI]=131.9-191.6), and median disease-free survival was 112.0 months (95% CI=88.7-180.4). Advanced stage was associated with decreased overall survival (adjusted p(trend)<0.001), and positive margins were associated with decreased disease-free survival (adjusted hazard ratio [aHR]=8.80, 95% CI=1.25-62.12, P = 0.029). Ninety-one tumors were evaluable using FISH, and 59 (65%) had evidence of a MYB-NFIB fusion. MYB-NFIB positive tumors were more likely than MYB-NFIB negative tumors to originate in minor salivary glands (adjusted prevalence ratios=1.51, 95% CI=1.07-2.12, P = 0.019). MYB-NFIB tumor status was not significantly associated with disease-free or overall survival (hazard ratio [HR]=1.53, 95% CI=0.77-3.02, P = 0.22 and HR=0.91, 95% CI=0.46-1.83, P = 0.80, respectively, for MYB-NFIB positive compared with MYB-NFIB negative tumors). ConclusionStage and margin status were important prognostic factors for ACC. Tumors with evidence of MYB-NFIB fusion were more likely to originate in minor salivary glands, but MYB-NFIB tumor status was not significantly associated with prognosis. Level of Evidence4. Laryngoscope, 125:E292-E299, 2015
引用
收藏
页码:E292 / E299
页数:8
相关论文
共 50 条
[41]   Head and neck adenoid cystic carcinoma: A prospective multicenter REFCOR study of 95 cases [J].
Meyers, M. ;
Granger, B. ;
Herman, P. ;
Janot, F. ;
Garrel, R. ;
Fakhry, N. ;
Poissonnet, G. ;
Baujat, B. .
EUROPEAN ANNALS OF OTORHINOLARYNGOLOGY-HEAD AND NECK DISEASES, 2016, 133 (01) :13-17
[42]   Clinical Outcomes and Prognostic Factors of Adenoid Cystic Carcinoma of the Head and Neck [J].
Jang, Samuel ;
Patel, Priyesh N. ;
Kimple, Randall J. ;
Mcculloch, Timothy M. .
ANTICANCER RESEARCH, 2017, 37 (06) :3045-3052
[43]   Prognostic importance of RUNX1 expression for head and neck adenoid cystic carcinoma [J].
Soares, Ciro Dantas ;
de Caceres, Cinthia Veronica Bardalez Lopez ;
Rodrigues-Fernandes, Carla Isabelly ;
de Lima Morais, Thayna Melo ;
de Almeida, Oslei Paes ;
de Carvalho, Maria Goretti Freire ;
Fonseca, Felipe Paiva .
ORAL DISEASES, 2021, 27 (02) :266-276
[44]   Treatment outcomes and prognostic features in adenoid cystic carcinoma originated from the head and neck [J].
Shen, Chunying ;
Xu, Tingting ;
Huang, Caiping ;
Hu, Chaosu ;
He, Shaoqin .
ORAL ONCOLOGY, 2012, 48 (05) :445-449
[45]   The clinical significance for primary tumor surgery in metastatic head and neck adenoid cystic carcinoma [J].
Zhang, Di ;
Li, Lixi .
EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2023, 280 (10) :4577-4586
[46]   Dominant cell type analysis predicts head and neck adenoid cystic carcinoma outcomes [J].
Xuan, Lanlan ;
Yuan, Jianwei ;
Zhang, Hong ;
Zhang, Ying ;
Liu, Honggang .
ANNALS OF DIAGNOSTIC PATHOLOGY, 2022, 56
[47]   Adenoid cystic carcinoma of the head and neck - An update [J].
Coca-Pelaz, Andres ;
Rodrigo, Juan P. ;
Bradley, Patrick J. ;
Poorten, Vincent Vander ;
Triantafyllou, Asterios ;
Hunt, Jennifer L. ;
Strojan, Primoz ;
Rinaldo, Alessandra ;
Haigentz, Missak, Jr. ;
Takes, Robert P. ;
Mondin, Vanni ;
Teymoortash, Afshin ;
Thompson, Lester D. R. ;
Ferlito, Alfio .
ORAL ONCOLOGY, 2015, 51 (07) :652-661
[48]   t(6;9)(MYB-NFIB) in head and neck adenoid cystic carcinoma: A systematic review with meta-analysis [J].
de Almeida-Pinto, Yasmin Dias ;
dos Santos Costa, Sara Ferreira ;
Benevenuto de Andrade, Bruno Augusto ;
Altemani, Albina ;
Vargas, Pablo Agustin ;
Abreu, Lucas Guimaraes ;
Fonseca, Felipe Paiva .
ORAL DISEASES, 2019, 25 (05) :1277-1282
[49]   Expression of MYB protein and its clinicopathological significance in adenoid cystic carcinoma of salivary gland [J].
Ding, Jie ;
Chen, Jun ;
Wang, Yujia ;
Shen, Hao ;
Yang, Yan ;
Huang, Xiaofeng .
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2016, 9 (05) :5096-5102
[50]   Detection of MYB Alterations and Other Immunohistochemical Markers in Primary Cutaneous Adenoid Cystic Carcinoma [J].
North, Jeffrey P. ;
McCalmont, Timothy H. ;
Fehr, Andre ;
van Zante, Annemieke ;
Stenman, Goran ;
LeBoit, Philip E. .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2015, 39 (10) :1347-1356